Topical Nano-Fibrous Ocular Patch-Indian Patent Filed

Features : • e-Auction Description of Work : Topical Nano-Fibrous Ocular Patch-Indian Patent Filed • e-Auction Type : NonExclusive • e-Auction Number : NE/KIHT/20015 • Base Price : 500000.00 • Licenses : 20 • e-Auction Category : Manufacturing Rights Transfer • e-Auction Date / Time : 13-07-2018 11:54 • TRL : 8 • TECHNICAL ABSTRACT OF THE INVENTION: • Present invention relates to nano-ocular patch, particular nanofibers for the delivery of therapeutic entities via ocular route. Nano-patch of present invention provides comfortable and controlled delivery of encapsulated therapeutics constantly over a period of several months. Nanofibers are used for ocular drug delivery carrier for the treatment of eye infections. • INTELLECTUAL PROPERTIES: • Patent application filled covering nanofiber patch for ocular delivery of therapeutics. • INVENTION: • Polymeric nanofibers with 100 % transmittance efficiency used for ocular drug delivery. • Polymeric nanofibers in terms of unit solid dosage form for ocular drug delivery of therapeutics. • Electrospun nanofibers for topical and inocular delivery of therapeutics. • Electrospun nanofibers for controlled drug delivery can be achieved with appropriate selection of polymer (Biodegradable or non-biodegradable). • Electrospun nanofibers for ocular delivery of broad range therapeutics. • SIGNIFICANCE OF DEVELOPED INVENTION: • It is unique kind of ocular solid dosage form that provide control dosing and dosage regimen in a precise manner. • Electrospun nanofibers due to its intrinsic properties offers high drug payload, improve solubility, higher permeability and enhanced bioavailability. Electrospun nanofibers provide prolonged and controlled release of encapsulated therapeutics. • Electrospun nanofibers improves product stability. • Nanometric architecture of Nanofibers provide sufficient flexibility for ocular applications. • Developed Formulation • TECHNOLOGY TRANSFER SUITABILITY: • Size, shape, thickness and surface characteristics of ocular patch can be easily manipulate from nano to micron as per the necessary pharmacokinetic and pharmacodynamics response. • Easy to scale-up. • Minimum additive requirement to help to meet the regulatory guideline for ophthalmic dosage form. • Single and automatic unit operational steps avoid the requirement of large head space for the large scale manufacturing. • Automatic and closed nature of developed technique make it easy to maintain sterile condition during the fabrication of nanofibers. • Developed product being unit solid dosage form avoid the wastage of formulations has observed in ophthalmic drug as per the schedule requirement (Discard the remaining quantity after month of its use). • Developed technology offers immense possibility for continuous production of nanofibers. • Developed product being solid dosage form offered ample flexibility in manufacturing, packaging, transportation and storage.